Arvinas Announces Interim Chief Commercial Officer

Stock.adobe.com

Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January.¹ While the company searches for a replacement, Alex Santini, senior vice president of global and US market access, is serving as interim chief commercial officer.

In a press release, Arvinas CEO and president John Houston, PhD, said, “Our commercial organization couldn’t be in a better position, and I look forward to working closely with Alex. He has been a highly valued member of the Arvinas team for multiple years, and his well-established ability to build and lead an outstanding commercial team will be invaluable as we prepare for our potential first launch alongside our partners at Pfizer. We thank John for his contributions to the business, particularly his efforts to begin building a strong commercial organization for launch.”

In the same press release, Houston provided updates for several products in the company’s pipeline. He also announced updated guidance for planned first- and second-line combination clinical trials for vepdegestrant in certain cancer patients.

He explained, “We are on the cusp of a major transformation in 2025, with the potential to provide significant benefit to patients and meaningful value to our stockholders. We are on track to report topline results from our first Phase 3 trial in the first quarter and to initiate two additional Phase 3 trials by the end of the year. In the first half of 2025, we plan to present the first-in-human data from ARV-102, our PROTAC LRRK2 degrader, which we believe will highlight the potential value that our PROTAC degraders may offer for patients with neurodegenerative diseases. And finally, we plan to share initial data from our Phase 1 trial with ARV-393, our PROTAC BCL6 degrader, which will provide an early look the tolerability and efficacy in patients with B-cell lymphomas.”

This is the latest change to Arvinas’ C-suite. In June of last year, the company announced that Andrew Saik had been named chief financial officer and treasurer.²

At the time, Houston said, “It is a pleasure to welcome Andrew as our new Chief Financial Officer. Andrew is a seasoned executive in biopharma finance with extensive experience in strategic financial leadership. His expertise in developing robust financial strategies will be invaluable as Arvinas builds out the financial systems and infrastructure necessary to transition to a commercial-stage biotech and continues to execute multiple ongoing clinical-stage programs to prepare for a Phase 3 data readout.”

In the same press release, Saik said, “I am delighted to join this dynamic team and contribute to the company's future successes. Arvinas has a remarkable track record in pioneering targeted protein degradation, and I believe that my experience in developing commercial strategies and guiding financial operations at late-stage companies will be instrumental as Arvinas builds and scales the financial systems and infrastructure necessary to support its ambitious growth plans and ensure the company is well-positioned as it transitions towards commercialization. This is a pivotal time for the company, and I am excited to be a part of its promising future and help build on the incredible momentum to date."

Sources

1. Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update. Arvinas. January 10, 2025. Accessed January 22, 2025. https://ir.arvinas.com/news-releases/news-release-details/arvinas-updates-guidance-first-and-second-line-phase-3
2. Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer. Arvinas. June 24, 2024. Accessed January 22, 2025. https://ir.arvinas.com/news-releases/news-release-details/arvinas-appoints-andrew-saik-chief-financial-officer-and